Changes in the expression of mexB, mexY, and oprD in clinical Pseudomonas aeruginosa isolates.

Phe-Arg-β-naphthylamide aminoglycoside acetyltransferase metallo-β-lactamase multidrug efflux pumps multidrug resistance

Journal

Proceedings of the Japan Academy. Series B, Physical and biological sciences
ISSN: 1349-2896
Titre abrégé: Proc Jpn Acad Ser B Phys Biol Sci
Pays: Japan
ID NLM: 9318162

Informations de publication

Date de publication:
2024
Historique:
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 10 1 2024
Statut: ppublish

Résumé

Changes in expression levels of drug efflux pump genes, mexB and mexY, and porin gene oprD in Pseudomonas aeruginosa were investigated in this study. Fifty-five multidrug-resistant P. aeruginosa (MDRP) strains were compared with 26 drug-sensitive strains and 21 strains resistant to a single antibiotic. The effect of the efflux inhibitor Phe-Arg-β-naphthylamide on drug susceptibility was determined, and gene expression was quantified using real-time quantitative real-time reverse transcription polymerase chain reaction. In addition, the levels of metallo-β-lactamase (MBL) and 6'-N-aminoglycoside acetyltransferase [AAC(6')-Iae] were investigated. Efflux pump inhibitor treatment increased the sensitivity to ciprofloxacin, aztreonam, and imipenem in 71%, 73%, and 29% of MDRPs, respectively. MBL and AAC(6')-Iae were detected in 38 (69%) and 34 (62%) MDRP strains, respectively. Meanwhile, 76% of MDRP strains exhibited more than 8-fold higher mexY expression than the reference strain PAO1. Furthermore, 69% of MDRP strains expressed oprD at levels less than 0.01-fold of those in PAO1. These findings indicated that efflux pump inhibitors in combination with ciprofloxacin or aztreonam might aid in treating MDRP infections.

Identifiants

pubmed: 38199247
doi: 10.2183/pjab.100.006
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

57-67

Auteurs

Yoshimi Matsumoto (Y)

SANKEN (The Institute of Scientific and Industrial Research), Osaka University.

Seiji Yamasaki (S)

SANKEN (The Institute of Scientific and Industrial Research), Osaka University.
Graduate School of Pharmaceutical Sciences, Osaka University.
Institute for Advanced Co-Creation Studies, Osaka University.

Kouhei Hayama (K)

SANKEN (The Institute of Scientific and Industrial Research), Osaka University.

Ryota Iino (R)

Institute for Molecular Science, National Institutes of Natural Sciences.
Graduate Institute for Advanced Studies, The Graduate University for Advanced Studies (SOKENDAI).

Hiroyuki Noji (H)

Graduate School of Engineering, The University of Tokyo.

Akihito Yamaguchi (A)

SANKEN (The Institute of Scientific and Industrial Research), Osaka University.

Kunihiko Nishino (K)

SANKEN (The Institute of Scientific and Industrial Research), Osaka University.
Graduate School of Pharmaceutical Sciences, Osaka University.
Center for Infectious Disease Education and Research, Osaka University.

Classifications MeSH